Global Overactive Bladder (OAB) Therapeutics Industry

Global Overactive Bladder (OAB) Therapeutics Industry

  • April 2021 •
  • 172 pages •
  • Report ID: 6051297 •
  • Format: PDF
Abstract:
- Global Overactive Bladder (OAB) Therapeutics Market to Reach $3.4 Billion by 2027
- Amid the COVID-19 crisis, the global market for Overactive Bladder (OAB) Therapeutics estimated at US$3.2 Billion in the year 2020, is projected to reach a revised size of US$3.4 Billion by 2027, growing at aCAGR of 0.9% over the period 2020-2027. Anticholinergic Agents, one of the segments analyzed in the report, is projected to record 0.7% CAGR and reach US$2.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Beta-3 Adrenoreceptor Agonists segment is readjusted to a revised 1.4% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $865.8 Million, While China is Forecast to Grow at 2% CAGR
- The Overactive Bladder (OAB) Therapeutics market in the U.S. is estimated at US$865.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$621.7 Million by the year 2027 trailing a CAGR of 2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at -0.2% and 0.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 0.1% CAGR.

- Select Competitors (Total 34 Featured) -
  • Allergan PLC
  • Astellas Pharma, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Endo Pharmaceuticals, Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Recordati SpA
  • Speciality European Pharma Ltd.
  • Sunovion Pharmaceuticals, Inc.